共查询到20条相似文献,搜索用时 687 毫秒
1.
目的:为检测HBV感染者基因型及血清 HBV cccDNA、HBV DNA、ALT、HBeAg水平,探讨它们之间相互关系及治疗后与这些指标的相关性,采用PCR荧光定量、基因测序、化学发光、生化分析等方法,分别对收集的202名HBV感染的患者治疗前后(经过使用抗病毒药物---拉米呋定,一个疗程)的血清HBV DNA、 cccDNA、 ALT、 HBeAg定量检测及HBV DNA基因分型。结果显示,HBV B型和C型患者的血清 HBV DNA和cccDNA的水平没有显著性差异,cccDNA与HBV DNA的比值也没有显著性差异;HBV B型和C型患者的血清 HBV DNA和cccDNA的水平与ALT有相关性;不管是HBV B型还是C型的患者,HBeAg阳性的病人血清中HBV DNA和cccDNA显著高于HBeAg阴性的病人;但是,C型的患者,HBeAg阳性的病人cccDNA与HBV DNA的比值显著低于HBeAg阴性的病人;治疗后比治疗前除 HBeAg没有显著性差异(P >0.05),HBV DNA、 cccDNA、 ALT均有显著性差异(P <0.01)。结论:感染HBV B型和C型的患者血清 HBV DNA和cccDNA的水平无显著性差异;而C型的患者,HBeAg阳性的病人cccDNA与HBV DNA的比值显著低于HBeAg阴性的病人;HBV基因型、HBV cccDNA、ALT与抗病毒治疗密切相关。 相似文献
2.
慢性乙型肝炎患者HBV cccDNA定量方法的建立及应用 总被引:3,自引:0,他引:3
目的 建立慢性乙型肝炎患者HBV cccDNA荧光定量检测方法 ,并检测慢性乙型肝炎患者血清中HBV cccDNA含量.方法 根据HBV DNA结构特点,于HBV cicada缺口两侧高度保守区域设计巢式PCR引物和探针,并优化PCR反应条件;选取175例慢性乙型肝炎患者,提取抗病毒治疗前后血清DNA,以不降解质粒的ATP依赖的DNA酶(PSAD)进行酶切,进行rcDNA定量检测;分析影响血清HBV cccDNA检出率的相关因素,探讨血清HBV cccDNA载量与慢性乙型肝炎患者临床特征的关系.结果 慢性乙型肝炎患者血清中可检测到HBV cccDNA.血清HBV cccDNA检出率与血清HBV DNA载量相关.HBeAg阳性慢性乙肝患者血清HBV cccDNA载量高于HBeAg阴性慢性乙肝患者.结论 本方法 具有较好的敏感性,可用于HBV cccDNA的检测. 相似文献
3.
目的 探讨聚乙二醇干扰素α-2a联合基因重组酵母乙肝疫苗治疗HBeAg阳性的慢性乙型肝炎患者疗效.方法 总75例HBeAg阳性慢性乙型肝炎纳入本研究,其中单用聚乙二醇干扰素α-2a治疗的45例(A组);聚乙二醇干扰素α-2a联合基因重组酵母乙肝疫苗的HBeAg阳性慢性乙肝患者30例(B组).对比分析两组在治疗0、24、48和72周时ALT、HBsAg水平、HBeAg血清转换率和HBV DNA阴转率的差异.结果 治疗前(0周)时两组患者的年龄、ALT、HBsAg和HBV DNA水平差异均无统计学意义(P>0.05),其中联合治疗组(B组)HBeAg水平明显高于对照组(A组),差异具有统计学意义(P<0.05).第24周和48周时,两组患者的ALT、HBsAg水平、HBeAg血清学转换率和HBV DNA阴转率差异并无统计学意义(P>0.05).在治疗结束随访至72周时,A、B两组ALT、HBeAg血清转换率和HBsAg水平差异没有统计学意义(P>0.05),但B组HBV DNA阴转率高于A组,差异具有统计学意义(P=0.032).结论 聚乙二醇干扰素α-2a联合基因重组乙肝疫苗治疗HBeAg阳性的慢性乙型肝炎患者可以提高48周治疗结束后72周时的HBV DNA阴转率,但是与HBeAg血清学转换和HBsAg水平降低无关. 相似文献
4.
目的 探讨阿德福韦酯治疗慢性乙型肝炎患者发生HBeAg血清学转换与HBV基因型、HBV特异性CTL的关系.方法 70例慢性乙型肝炎患者HBV DNA阳性(HBV DNA≥1×104拷贝/ml),HBeAg阳性45例,其中B基因型23例(51.11%),C基因型22例(48.89%).ALT>2×正常参考值上限(ULN)、人白细胞抗原(HLA)-A2阳性,用阿德福韦酯(正大天睛药业公司生产)10 mg,口服,每日1次.观察治疗12个月后HBeAg血清学转换与HBV基因型、HBV特异性CTL的关系.结果 阿德福韦酯治疗12个月后,HBV特异性CTL(0.68%±0.11%)高于治疗前(0.33%±0.11%),t=8.36 P<0.001,HBV DNA(3.01±0.2)log10拷贝/ml低于治疗前[(6.27 ±0.70)log10拷贝/ml]t=12.63 P<0.001,HBV DNA阴转(<500拷贝/ml)43例(61.43%).HBeAg阳性45例中发生HBeAg转阴13例(28.89%),HBeAg血清学转换8例(17.78%),HBeAg血清学转换者HBV特异性CTL(0.86 ±0.05%)高于无HBeAg血清学转换者(37例,82.22%)的HBV特异性CTL(0.61%±0.07%),t=7.88,P<0.001.HBeAg血清学转换8例中,B基因型7例(占B基因型30.43%),C基因型1例(占C基因型4.55%),x2=5.15,P<0.05.结论 阿德福韦酯能提高CHB患者的HBV特异性细胞免疫功能,治疗后HBeAg血清学转换的发生与HBV特异性CTL水平升高有关,并可能与基因型有关. 相似文献
5.
目的 探讨血清HBV 前基因组RNA(pgRNA)在HBV相关疾病中的表达及其临床意义。方法 收集90例慢性乙型肝炎、54例乙肝肝硬化和44例HBsAg阳性原发性肝癌患者血清样本,进行HBsAg、HBeAg、HBV DNA和HBV pgRNA检测。结果 血清HBV pgRNA水平在慢性乙型肝炎组、肝硬化组、肝癌组患者中的中位数分别为7.08、5.16 和4.08 log copies/mL ,差异有统计学意义(χ^2=24.743, P <0.001)。在HBeAg阳性患者中,HBV pgRNA水平在慢性乙型肝炎组、肝硬化组、肝癌组患者中逐渐降低,差异有统计学意义(χ^2=14.864, P <0.001);且血清HBV pgRNA水平与血清HBV DNA、HBsAg水平及HBeAg滴度呈正相关。而在HBeAg阴性患者中,血清HBV pgRNA水平与血清HBV DNA、HBsAg水平及HBeAg滴度无相关性。结论 血清HBV pgRNA水平在慢性乙型肝炎、肝硬化和肝癌患者中逐渐降低,且与HBV DNA、HBsAg水平及HBeAg滴度呈正相关。 相似文献
6.
目的 探讨HBV感染指标、病毒复制水平和基因型之间的关联及对乙肝患者诊断和预后的意义.方法 采用酶联免疫吸附试验(ELISA)检测样本的HBV PreS1-Ag、Anti-HBc-IgM和HBV两对半;荧光定量PCR法测HBV DNA水平;巢氏PCR法扩增S片段、测序并对比分析判定基因型,联合分析指标的关联.结果 收集河南地区急、慢性乙肝患者样本355例.模式Ⅰ(HBeAg阳性)的PreS1-Ag阳性率为80.2%、HBV DNA阳性率为73.7%,显著高于其他模式;PreS1-Ag、Anti-HBc-IgM阳性者的ALT、AST异常率显著高于阴性组;HBV基因型结果为B型4例(2.9%),C型76例(55.9%),D型56例(41.2%),C型患者的HBeAg和HBV DNA阳性率显著高于B型和D型.结论 PreS1-Ag和Anti-HBc-IgM对乙肝早期诊断、病毒复制监测及预后评估有重要意义;河南地区乙肝患者的HBV基因型以C型和D型为主,C型的HBeAg和HBV DNA阳性率显著高于B和D型. 相似文献
7.
HBV基因分型与病毒载量及血清标志物关系的探讨 总被引:1,自引:0,他引:1
目的探讨HBV基因型与HBV-DNA水平及血清标志物的相关性。方法选择125例乙肝患者血清HBV-DNA复制阳性的标本分别检测HBV病毒基因分型、HBV-DNA、乙肝血清标志物、谷丙转氨酶(ALT)和总胆红素(TBL)。结果 125例HBV-DNA复制阳性标本中HBV基因分型以B型为主占71.2%(89/125),C型占24.0%(30/125),BC混合型占2.4%(3/125),非B非C型占2.4%(3/125);B基因型患者血清ALT(297.3±193.6)U/L和TBL(105.1±59.7)mol/L水平高于C基因型患者ALT(158.1±107.5)U/L和TBL(53.1±22.7)mol/L,P〈0.01;B基因型患者血清抗-HBe阳性率91.0%(81/89)显著高于C基因型的23.3%(7/30),P〈0.01;B型HBV-DNA水平(5.87±1.72)log10copies/mL与C型(6.01±1.91)log10copies/mL无差异(P〉0.05)。结论本地区HBV病毒基因型以B型为主,C型次之,B基因型对肝脏损害较C基因型重,并与HBV载量及HBeAg系统具有相关性,B基因型易发生YMDD突变。 相似文献
8.
目的了解邯郸市乙肝病毒基因型分布情况,并探讨其与临床的关系。方法采用PCR—RFLP方法对邯郸108份HBV感染者的血清进行基因型分型,并结合转氨酶和HBV—DNA结果,分析乙肝病毒基因型的临床意义。结果邯郸市慢性乙肝人群感染的HBV主要以C基因型为主,占93.5%,B基因型占6、5%。不同性别感染基因型差异无统计学意义。肝生化指标ALT、AST、TB比较提示c基因型患者的肝脏炎症似乎比B型患者重,但差异无统计学意义。C基因型的患者血清HBeAg阳性率高于B基因型。C基因型的患者血清HBV—DNA略高于B基因型,但无统计学差异。结论邯郸市慢性乙肝人群感染的HBV主要以C基因型为主。C基因型患者血清HBeAg阳性率高于B基因型,C基因型患者与B基因型相比肝脏炎症较重,HBV—DNA略高,但差异无统计学意义。 相似文献
9.
慢性乙型肝炎患者肝功能及血清HBeAg和HBV DNA载量与肝组织病理相关性的研究 总被引:1,自引:0,他引:1
目的 探讨慢性乙型肝炎患者肝功能、HBeAg及HBV DNA水平与肝组织病理炎症分级和纤维化分期的关系.方法 选择233例慢性乙型肝炎患者进行肝穿病理学检查,同时所有患者检测HBV DNA、HBeAg及肝功能,比较患者的肝功能、HBeAg及HBV DNA水平在不同病理炎症分级及纤维化分期中的差异情况.结果 不同的炎症分级患者中,ALT以C3组最高,G0~1组最低,各组间比较差异有统计学意义(P =0.016);TBil以G4组最高,G0~1组最低,各组间比较差异有统计学意义(P=0.000);HBV DNA载量各组间差异无统计学意义.不同的纤维化分期患者中,ALT各组间比较差异无统计学意义;TBil以S4组最高,S2组最低,各组间比较差异有统计学意义(P=0.039);HBV DNA载量各组间差异无统计学意义.炎症分级为G3~4的患者比例在HBeAg阳性组与阴性组差异无统计学意义.纤维化分期S3~4的患者比例在HBeAS阳性组(38%)比HBeAg阴性组(53%)低,两组差异有统计学意义(P=0.025).结论 慢性乙型肝炎患者血清HBV DNA水平的高低不能反映其肝脏炎症及纤维化程度,HBeAg阴性慢乙肝患者肝组织纤维化程度较高,TBil水平与肝组织炎症分级及纤维化分期均有良好的相关性,ALT水平与炎症分级有一定的关联性,但与纤维化分期无关. 相似文献
10.
目的 比较原发性肝癌与乙型肝炎肝硬化患者的血清HBV DNA水平、HBV基因型差别。方法 对210例原发性肝癌(HCC)患者及220例乙型肝炎肝硬化(HBV LC)患者的血清HBVDNA水平及HBV基因型进行分析,比较病毒学和基因型差异。结果 210例HCC患者和220例HBV LC患者HBV DNA检测阳性率分别为84.3%(177/210)、94.5%( 208/220);HBV DNA定量为(5.06±1.01) log10拷贝/ml和(5.36±1.13)log10拷贝/ml,HBV LC患者均高于HCC患者(P<0.01);HCC组和HBV LC组均以C基因型为主,两组B,C基因型分布无明显差异。结论 HCC患者血清HBV DNA水平低于HBV LC患者。两组HBV基因型分布无明显差异,均以C基因型为多。 相似文献
11.
12.
R.B. Takkenberg H.L. Zaaijer R. Molenkamp S. Menting V. Terpstra C.J. Weegink M.G.W. Dijkgraaf P.L.M. Jansen H.W. Reesink M.G.H.M. Beld 《Journal of medical virology》2009,81(6):988-995
Hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) serves as a template for viral replication and plays a role in persistence of HBV infection. The origin and significance of cccDNA in plasma however, is not well understood. A sensitive, specific, and reproducible real‐time PCR for detection and quantitation of cccDNA in plasma of chronic hepatitis B patients was developed and validated. Four HBV DNA reference panels, and 96 plasma samples of chronic hepatitis B patients were analyzed. Results were compared with total HBV DNA levels, individual ALT levels and the Histology Activity Index (HAI). This cccDNA assay had a lower limit of detection at 15 copies/PCR, a lower limit of quantitation at 91 copies/PCR and a correlation coefficient (R) of 0.98 (P < 0.0001). cccDNA was detected in two of four international panels. Significant correlation was found between cccDNA and total HBV DNA levels in both panels (R = 0.96, and R = 0.43) and in samples of the chronic hepatitis B patients (R = 0.88, P < 0.0001). In 57% of these samples cccDNA was detectable. Mean level of cccDNA was 0.16% of total HBV load. Plasma cccDNA levels were higher in HBeAg positive samples than in HBeAg negative samples (4.91 log copies/ml vs. 3.88 log copies/ml, P < 0.0001). Levels of total HBV DNA and HBV genotype did not influence cccDNA detection. ALT levels and HAI‐score were not correlated with plasma cccDNA levels. These findings suggest that cccDNA levels in plasma are not the result of increased hepatocyte degeneration, but indicate that other mechanisms might be responsible. J. Med. Virol. 81:988–995, 2009. © 2009 Wiley‐Liss, Inc. 相似文献
13.
Carol J. Morris Mary Hill Maria de Medina Christine Herman Gavin A. Cloherty Paul Martin 《Journal of virological methods》2013
Monitoring the serum hepatitis B viral DNA levels with sensitive realtime PCR assays is strongly recommended for the management of patients with chronic HBV infection. This study compares the performance of two realtime HBV quantitative PCR assays with samples from chronic HBeAg(+) and HBeAg(−) patients. 相似文献
14.
Fumitaka Suzuki Hideo Miyakoshi Mariko Kobayashi Hiromitsu Kumada 《Journal of medical virology》2009,81(1):27-33
Nucleos(t)ide analogues are utilized for the treatment of chronic HBV infection, and HBe seroconversion and HBV DNA levels are commonly used as markers of viral status and as primary treatment endpoints. Recently, a new assay was prepared for the detection of serum HBV core‐related antigen (HBcrAg), consisting of HBcAg, HBeAg, and p22cr, which is a precore protein from amino acid ?28 to at least amino acid 150, by coding the precore/core region. In this study, we examined the correlation between serum HBcrAg concentration and viral status by the analysis of serum HBeAg, HBsAg, peripheral HBV DNA, and intrahepatic covalently closed circular DNA (cccDNA) in 57 chronic hepatitis B patients. Intrahepatic cccDNA was detected in all 57 patients, 42 patients were HBcrAg‐positive, and serum HBcrAg concentration level was closely correlated with cccDNA. Additionally, positive HBcrAg concentration level results were observed in 6 out of 13 HBsAg seroclearance patients and 20 out of 31 HBV DNA‐negative patients. Moreover, the correlation between HBcrAg and cccDNA in these 31 HBV DNA‐negative patients was statistically significant (r = 0.482, P = 0.006). These data suggest that serum HBcrAg concentration is well correlated with intrahepatic cccDNA level, and that the measurement of serum HBcrAg may be clinically useful for monitoring intrahepatic HBV viral status, especially in patients under treatment with nucleos(t)ide analogues. J. Med. Virol. 81:27–33, 2009. © 2008 Wiley‐Liss, Inc. 相似文献
15.
H Sakugawa H Nakasone T Nakayoshi Y Kawakami T Yamashiro T Maeshiro F Kinjo A Saito H Zukeran 《Journal of medical virology》2001,65(3):478-484
To clarify the correlation between hepatitis B virus (HBV) DNA levels and serum alanine aminotransferase (ALT) levels in patients with established chronic hepatitis delta virus (HDV) infection, sensitive HBV quantitative assays were used for the study. Thirty-four consecutive patients with chronic liver disease who were positive for both hepatitis B surface antigen (HBsAg) and antibody to HDV (anti-HDV), including 19 patients with chronic hepatitis, 8 patients with liver cirrhosis and 7 patients with hepatocellular carcinoma. All were negative for hepatitis Be antigen (HBeAg) and positive for antibody to HBeAg. HBV DNA was detected in 25 (73.5%) of the 34 patients using real-time detection PCR, and the HBV DNA levels of these patients were significantly lower compared with HBeAg status and ALT level-matched patients with chronic liver disease positive for HBsAg but negative for anti-HDV. There was no correlation between serum HBV DNA and ALT levels among the 34 patients with chronic liver disease positive for anti-HDV. Whereas serum ALT levels in anti-HDV-positive HBsAg carriers with HDV RNA were significantly higher than those without HDV RNA. Liver damage in patients with established chronic HDV infection may be caused mainly by ongoing HDV infection not by HBV replication. 相似文献
16.
17.
L.Y. Lin V.W.S. Wong H.J. Zhou H.Y. Chan H.L. Gui S.M. Guo H. Wang L. Huang S.S. Bao Q. Xie H.L.Y. Chan 《Journal of medical virology》2010,82(9):1494-1500
Hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) is responsible for viral persistence. This study aimed to investigate the serum surrogate markers for cccDNA and to evaluate the intrahepatic viral events associated with disease activity in HBeAg‐negative chronic hepatitis B patients. Thirty‐three treatment‐naïve patients with a negative HBeAg who had a liver biopsy were studied. Active disease was defined as a serum alanine aminotransferase >40 IU/L and a serum HBV DNA >10,000 copies/ml. This study showed significant correlation between serum HBV DNA and both log cccDNA (r = 0.41, P = 0.018) and log total intrahepatic HBV DNA (r = 0.71, P < 0.0001). No significant correlation was observed between serum HBsAg and log cccDNA (P = 0.15) or log total intrahepatic HBV DNA (P = 0.97). Fourteen and 19 patients had inactive and active disease, respectively. The median log cccDNA and log total intrahepatic HBV DNA (copies/106 cells) were significantly higher in patients with active disease compared with those with inactive disease (4.11 vs. 3.53, P = 0.03 and 5.46 vs. 4.64, P < 0.001, respectively). The HBV replicative efficiency, defined as the ratio of serum HBV DNA to cccDNA, was approximately 20% higher in patients with active disease. No significant difference was observed in the HBsAg levels and the ratio of serum HBsAg to cccDNA between the two groups. In conclusion, serum HBV DNA, but not HBsAg, reflects the amount of cccDNA and the replication efficiency of HBV in patients with HBeAg‐negative chronic hepatitis B. J. Med. Virol. 82:1494–1500, 2010. © 2010 Wiley‐Liss, Inc. 相似文献
18.
The aim of the present study was to compare the decline of HBV DNA during peginterferon (PEG-IFN) therapy with spontaneous HBV DNA decline in placebo-treated patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. A total of 136 patients who participated in a randomized trial were treated with PEG-IFN alfa-2b for 52 weeks. These patients were compared with 167 patients who received a placebo for 48 weeks using linear mixed regression analysis. Response was defined as loss of HBeAg at the end of treatment (EOT). Overall, decline of HBV DNA at the EOT was significantly greater in the PEG-IFN group than in the placebo group (mean decline 2.3 log vs. 1.0 log, P < 0.001) and varied according to HBV genotype. Viral suppression was greater in the PEG-IFN group from week 4 throughout the entire treatment period (P < 0.001). The response rate was 32% for the PEG-IFN group and 11% for the placebo group (P < 0.001). Among responders, HBV DNA decline was greater for patients treated with PEG-IFN than with a placebo: the mean difference in HBV DNA decline was 0.7 log (P = 0.001) at 4 weeks and 2 log (P < 0.001) at the EOT. ALT flares (>5 times the upper limit) were associated with a greater HBV DNA decline during PEG-IFN. In conclusion, PEG-IFN therapy resulted in a greater HBV DNA decline in positive HBeAg patients than a placebo. The decline of HBV DNA was greater in patients with HBeAg loss or who exhibited an ALT flare during PEG-IFN than in patients with spontaneous HBeAg loss or flares during placebo therapy. 相似文献
19.
Yang Wang Yanna Liu Hao Liao Zhongping Deng Dandan Bian Yan Ren Guangxin Yu Yingying Jiang Li Bai Shuang Liu Mei Liu Li Zhou Yu Chen Xinyue Chen Zhongping Duan Fengmin Lu Sujun Zheng 《International journal of medical sciences》2022,19(5):858
Background & Aims: Correlations between serum viral markers and intrahepatic cccDNA in patients undergoing long-term nucleos(t)ide analogues (NAs) treatment haven''t been fully explored. In this study, we evaluate the correlation between intrahepatic cccDNA and other serum viral markers and intrahepatic HBV DNA in HBeAg positive chronic hepatitis B (CHB) patients during 60-month treatment with NAs.Methods: Fifty-four HBeAg positive CHB patients received long-term NAs treatment were included in this study. Serial serum samples were regularly collected and quantitatively analyzed for HBsAg, HBV DNA, HBV RNA and HBcrAg. Histological samples from liver biopsy at baseline and month 60 were analyzed for intrahepatic HBV DNA and cccDNA.Results: At baseline, serum HBV DNA plus RNA was positively associated with intrahepatic cccDNA in multivariate regression analysis (β=0.205, P<0.001). In the correlation analysis between cccDNA and serum viral markers, HBV DNA plus RNA had the highest correlation coefficient (r=0.698, P<0.001), followed by serum HBV DNA (r=0.641, P<0.001), HBV RNA (r=0.590, P<0.001), and HBcrAg (r=0.564, P<0.001). At month 60, correlations between these serum viral markers and cccDNA were not observed (P>0.05). Multivariate regression analysis showed that only the decreased HBV DNA plus RNA was positively associated with cccDNA decline (β=0.172, P =0.006). Changes of HBV DNA plus RNA (r=0.525, P=0.001) was better correlated with cccDNA decline as compared to HBV RNA (r=0.384, P=0.008), HBV DNA (r=0.431, P=0.003), and HBsAg (r=0.342, P=0.029).Conclusions: Serum HBV DNA plus RNA better correlated with intrahepatic cccDNA than other viral makers before and during NAs treatment in HBeAg positive CHB patients. 相似文献
20.
卢罗生 《广东寄生虫学会年报》2008,(5):474-476
目的探讨慢性乙型肝炎患者抗病毒治疗与血清脂质水平的关系。方法测定50例慢性乙型肝炎患者抗病毒治疗前后的的血清总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、血清载脂蛋白A1(apoA1)和载脂蛋白B(apoB)和HBV-DNA,并进行对比分析。结果慢性乙型肝炎患者血清的脂质水平随着血清HBVDNA载量高低程度而变化,随着病毒载量的升高而逐渐降低,抗病毒治疗前后比较,差异有统计学意义(P〈0.05)。结论测定血清脂质水平对判断较重的慢性肝炎肝组织实质细胞的损害有一定的价值。抗病毒治疗可以帮助恢复慢性乙型肝炎患者的血脂代谢. 相似文献